SLP News and Press, Simulations Plus Inc. From 08/27/25

New York, New York--(Newsfile Corp. - August 27, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are enco...

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’...

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting...

2025-08-04 12:07:00 ET At a glance Performance The Fund returned 8.44% and the Russell 2000® Growth Index returned 11.97%. Contributors/detractors Read the full article on Seeking Alpha For further details see: Janus Henderson Venture Fund Q2 2025 Commen...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP ) for violations of the securities laws. The inv...

New York, New York--(Newsfile Corp. - July 30, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Simulations Plus, Inc. ("Simulations Plus, Inc.") (NASDAQ: SLP) concerning possible violations of federal securities laws. Simulations Plus reported its financ...

Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance ...

2025-07-23 12:30:00 ET 2Q25 Performance & Attribution The Conestoga Micro Cap Composite advanced 15.65% net-of-fees in the second quarter but struggled to keep up with the 20.92% return of the Russell Microcap Growth Index, which was a sharp snapback from the benchmark's -17...

2025-07-23 11:00:00 ET Performance & Attribution The Conestoga Small Cap Composite returned 4.76% net-of-fees in the second quarter, underperforming the Russell 2000 Growth Index's return of 11.97%. The strategy began the quarter by building a significant advantage relative ...

2025-07-17 05:55:54 ET ... Read the full article on Seeking Alpha For further details see: Simulations Plus: Still Positioned For FDA In‑Silico Trend Despite Near‑Term Headwinds